<DOC>
	<DOC>NCT00569491</DOC>
	<brief_summary>The TAXUS ARRIVE study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.</brief_summary>
	<brief_title>TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Appropriate Patient Criteria: Patient is eligible to receive a Boston Scientific TAXUS Stent. Inappropriate Patients Criteria: Known sensitivity to paclitaxel. Known allergy to stainless steel. Patients in whom antiplatelet and / or anticoagulant therapy is contraindicated. Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device. Patients with unresolved vessel thrombus at the lesion site. Patients with coronary artery reference vessel diameters &lt; 2.5 mm or &gt; 3.75 mm. Patients with lesions located in the left main coronary artery, ostial lesions, or lesions located at a bifurcation. Patients with diffuse disease or poor overflow distal to the identified lesions. Patients with tortuous vessels in the region of the obstruction or proximal to the lesion. Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>